Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Elizabeth Dunbar
ST. PAUL, Minn.

Mayo study: 'Smart' stem cells help heart failure patients

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Treating heart failure patients with a special type of stem cell can improve their condition, according to a new Mayo Clinic study published this week.

The researchers used proteins to instruct the stem cells to behave like heart cells. All of the 45 patients in the clinical trial who received the "smart" stem cells saw more improvements in heart health than another group of patients who were given the standard treatments for heart failure.

The stem cell group's hearts were able to pump more robustly and the patients showed improvements in physical fitness, such as being able to walk longer distances than the patients who didn't receive the cells.

Dr. Andre Terzic, who led the research and is director of Mayo's Center for Regenerative Medicine, said it is the first published study in which smart stem cells were tested on humans.

"I think it's an exciting time where regenerative medicine is no longer science fiction but it's increasingly becoming considered as a viable option for our patients, in particular the patients [who] have many unmet needs that current therapies cannot address," Terzic said.

Terzic said the treatment will be tested on a group of 300 patients before researchers ask federal regulators to approve it, but he said he is hopeful because there were no patients in the current study who saw negative results. The study is published in the Journal of the American College of Cardiology.

Terzic said he also thinks the concept can be applied to other conditions.

"It will be, for example, fantastic to see cells instructed to be more neuron-like, to maybe go after some of the neurological disorders, or to be more bone-like to help an orthopedic surgery and so on," he said.

Mayo disclosed that Terzic and the clinic have a financial interest related to technology in the research program. Mayo has rights to future royalties from Cardio3 BioSciences, a Belgium-based biotechnology company working on regenerative therapies for cardiovascular diseases.